atcMA03AX15 202101262021031825000101pebermynteolie SKS 1 atcMA05BA09 202101262021031825000101metadoxin SKS 1 atcMA06AX08 202101262021031825000101tenapanor SKS 1 atcMA10BJ07 202101262021031825000101beinaglutid SKS 1 atcMA16AX17 202101262021031825000101triheptanoin SKS 1 atcMA16AX18 202101262021031825000101lumasiran SKS 1 atcMC01DX22 202101262021031825000101vericiguat SKS 1 atcMC09C 199705162021031820210331angiotensin II antagonister SKS 3 atcMC09C 202104012021031825000101angiotensin II receptor blokkere (ARBS), usammensatte SKS 1 atcMC09CA 199705162021031820210331angiotensin II antagonister, usammensatte SKS 3 atcMC09CA 202104012021031825000101angiotensin II receptor blokkere (ARBS), usammensatte SKS 1 atcMC09D 199705162021031820210331angiotensin II antagonister, kombinationer SKS 3 atcMC09D 202104012021031825000101angiotensin II receptor blokkere (ARBS), kombinationer SKS 1 atcMC09DA 199705162021031820210331angiotensin II antagonister og diuretica SKS 3 atcMC09DA 202104012021031825000101angiotensin II receptor blokkere (ARBS) og diuretica SKS 1 atcMC09DB 200704012021031820210331angiotensin II antagonister og calciumantagonister SKS 3 atcMC09DB 202104012021031825000101angiotensin II receptorblok. (ARBS) og calciumantagon. (CCB) SKS 1 atcMC10BA 200604012021031820210331HMG CoA reductase-inhib. i komb. med andre lipid-mod. midler SKS 3 atcMC10BA 202104012021031825000101lipid-modificerende midler, kombinationer SKS 1 atcMC10BA10 202101262021031825000101bempedoinsyre og ezetimib SKS 1 atcMC10BX 200604012021031820210331HMG CoA reductase-inhibitorer, andre kombinationer SKS 3 atcMC10BX 202104012021031825000101lipid-modificerende midler i komb. med andre lægemidler SKS 1 atcMD01BA03 202101262021031825000101fosravuconazol SKS 1 atcMD05AX55 202101262021031825000101tazaroten og ulobetasol SKS 1 atcMD06BX03 202101262021031825000101tirbanibulin SKS 1 atcMD10AF07 202101262021031825000101minocyclin SKS 1 atcMD11AH07 202101262021031825000101tralokinumab SKS 1 atcMG03AA18 202101262021031825000101drospirenon og estetrol SKS 1 atcMH01CC54 202101262021031825000101relugolix, estradiol og norethisteron SKS 1 atcMJ01MA25 202101262021031825000101lascufloxacin SKS 1 atcMJ04AK08 202101262021031825000101pretomanid SKS 1 atcMJ05AJ 202101262021031825000101integrasehæmmere SKS 1 atcMJ05AJ01 202104012021031825000101raltegravir SKS 1 atcMJ05AJ02 202104012021031825000101elvitegravir SKS 1 atcMJ05AJ03 202104012021031825000101dolutegravir SKS 1 atcMJ05AJ04 202101262021031825000101cabotegravir SKS 1 atcMJ05AX08 200804012021031820210331raltegravir SKS 3 atcMJ05AX11 201304012021031820210331elvitegravir SKS 3 atcMJ05AX12 201404012021031820210331dolutegravir SKS 3 atcMJ07BB04 202104012021031825000101influenza, viruslignende partikler SKS 1 atcMJ07BX01 201604012021031820210331koppevirus, levende svækket SKS 3 atcMJ07BX01 202104012021031825000101koppevaccine SKS 1 atcMJ07BX02 202101262021031825000101ebolavirus SKS 1 atcML01CE 202104012021031825000101topoisomerase 1 hæmmere SKS 1 atcML01CE01 202104012021031825000101topotecan SKS 1 atcML01CE02 202104012021031825000101irinotecan SKS 1 atcML01CE03 202104012021031825000101etirinotecan pegol SKS 1 atcML01CE04 202104012021031825000101belotecan SKS 1 atcML01E 202104012021031825000101proteinkinasehæmmere SKS 1 atcML01EA 202104012021031825000101BCR-ABL tyrosinkinasehæmmere SKS 1 atcML01EA01 202104012021031825000101imatinib SKS 1 atcML01EA02 202104012021031825000101dasatinib SKS 1 atcML01EA03 202104012021031825000101nilotinib SKS 1 atcML01EA04 202104012021031825000101bosutinib SKS 1 atcML01EA05 202104012021031825000101ponatinib SKS 1 atcML01EB 202104012021031825000101epidermal vækstfaktor receptor (EGFR)-tyrosinkinasehæmmere SKS 1 atcML01EB01 202104012021031825000101gefitinib SKS 1 atcML01EB02 202104012021031825000101erlotinib SKS 1 atcML01EB03 202104012021031825000101afatinib SKS 1 atcML01EB04 202104012021031825000101osimertinib SKS 1 atcML01EB05 202104012021031825000101rociletinib SKS 1 atcML01EB06 202104012021031825000101olmutinib SKS 1 atcML01EB07 202104012021031825000101dacomitinib SKS 1 atcML01EB08 202104012021031825000101icotinib SKS 1 atcML01EC 202104012021031825000101b-raf serin-threoninkinase (BRAF) hæmmere SKS 1 atcML01EC01 202104012021031825000101vemurafenib SKS 1 atcML01EC02 202104012021031825000101dabrafenib SKS 1 atcML01EC03 202104012021031825000101encorafenib SKS 1 atcML01ED 202104012021031825000101anaplastisk lymfom kinase (ALK) hæmmere SKS 1 atcML01ED01 202104012021031825000101crizotinib SKS 1 atcML01ED02 202104012021031825000101ceritinib SKS 1 atcML01ED03 202104012021031825000101alectinib SKS 1 atcML01ED04 202104012021031825000101brigatinib SKS 1 atcML01ED05 202104012021031825000101lorlatinib SKS 1 atcML01EE 202101262021031825000101mitogen-aktiverede proteinkinase (MEK) hæmmere SKS 1 atcML01EE01 202104012021031825000101trametinib SKS 1 atcML01EE02 202104012021031825000101cobimetinib SKS 1 atcML01EE03 202104012021031825000101binimetinib SKS 1 atcML01EE04 202101262021031825000101selumetinib SKS 1 atcML01EF 202104012021031825000101cyclin-afhængig kinase (CDK) hæmmere SKS 1 atcML01EF01 202104012021031825000101palbociclib SKS 1 atcML01EF02 202104012021031825000101ribociclib SKS 1 atcML01EF03 202104012021031825000101abemaciclib SKS 1 atcML01EG 202104012021031825000101mammalian target of rapamycin (mTOR) kinase hæmmere SKS 1 atcML01EG01 202104012021031825000101temsirolimus SKS 1 atcML01EG02 202104012021031825000101everolimus SKS 1 atcML01EG03 202104012021031825000101ridaforolimus SKS 1 atcML01EH 202101262021031825000101human epidermal vækstf.recep. 2 (HER2) tyrosinkinase hæmmere SKS 1 atcML01EH01 202104012021031825000101lapatinib SKS 1 atcML01EH02 202104012021031825000101neratinib SKS 1 atcML01EH03 202101262021031825000101tucatinib SKS 1 atcML01EJ 202104012021031825000101janus associerede kinase (JAK) hæmmere SKS 1 atcML01EJ01 202104012021031825000101ruxolitinib SKS 1 atcML01EJ02 202104012021031825000101fedratinib SKS 1 atcML01EK 202104012021031825000101vask. endotelial vækstf.recep. (VEGFR)-tyrosinkinase hæmmere SKS 1 atcML01EK01 202104012021031825000101axitinib SKS 1 atcML01EK02 202104012021031825000101cediranib SKS 1 atcML01EK03 202104012021031825000101tivozanib SKS 1 atcML01EL 202101262021031825000101bruton's tyrosinkinase (BTK) hæmmere SKS 1 atcML01EL01 202104012021031825000101ibrutinib SKS 1 atcML01EL02 202104012021031825000101acalabrutinib SKS 1 atcML01EL03 202101262021031825000101zanubrutinib SKS 1 atcML01EM 202101262021031825000101phosphatidylinositol-3-kinase (Pi3K) hæmmere SKS 1 atcML01EM01 202104012021031825000101idelalisib SKS 1 atcML01EM02 202104012021031825000101copanlisib SKS 1 atcML01EM03 202104012021031825000101alpelisib SKS 1 atcML01EM04 202101262021031825000101duvelisib SKS 1 atcML01EX 202101262021031825000101andre proteinkinasehæmmere SKS 1 atcML01EX01 202104012021031825000101sunitinib SKS 1 atcML01EX02 202104012021031825000101sorafenib SKS 1 atcML01EX03 202104012021031825000101pazopanib SKS 1 atcML01EX04 202104012021031825000101vandetanib SKS 1 atcML01EX05 202104012021031825000101regorafenib SKS 1 atcML01EX06 202104012021031825000101masitinib SKS 1 atcML01EX07 202104012021031825000101cabozantinib SKS 1 atcML01EX08 202104012021031825000101lenvatinib SKS 1 atcML01EX09 202104012021031825000101nintedanib SKS 1 atcML01EX10 202104012021031825000101midostaurin SKS 1 atcML01EX11 202104012021031825000101quizartinib SKS 1 atcML01EX12 202104012021031825000101larotrectinib SKS 1 atcML01EX13 202104012021031825000101gilteritinib SKS 1 atcML01EX14 202104012021031825000101entrectinib SKS 1 atcML01EX15 202101262021031825000101pexidartinib SKS 1 atcML01EX16 202101262021031825000101erdafitinib SKS 1 atcML01EX17 202101262021031825000101capmatinib SKS 1 atcML01EX18 202101262021031825000101avapritinib SKS 1 atcML01EX19 202101262021031825000101ripretinib SKS 1 atcML01EX20 202101262021031825000101pemigatinib SKS 1 atcML01EX21 202101262021031825000101tepotinib SKS 1 atcML01XC41 202101262021031825000101trastuzumab deruxtecan SKS 1 atcML01XE01 200704012021031820210331imatinib SKS 3 atcML01XE02 200704012021031820210331gefitinib SKS 3 atcML01XE03 200704012021031820210331erlotinib SKS 3 atcML01XE04 200704012021031820210331sunitinib SKS 3 atcML01XE05 200704012021031820210331sorafenib SKS 3 atcML01XE06 200704012021031820210331dasatinib SKS 3 atcML01XE07 200804012021031820210331lapatinib SKS 3 atcML01XE08 200804012021031820210331nilotinib SKS 3 atcML01XE09 200804012021031820210331temsirolimus SKS 3 atcML01XE10 201004012021031820210331everolimus SKS 3 atcML01XE11 201004012021031820210331pazopanib SKS 3 atcML01XE12 201104012021031820210331vandetanib SKS 3 atcML01XE13 201203012021031820210331afatinib SKS 3 atcML01XE14 201203012021031820210331bosutinib SKS 3 atcML01XE15 201203012021031820210331vemurafenib SKS 3 atcML01XE16 201203012021031820210331crizotinib SKS 3 atcML01XE17 201203012021031820210331axitinib SKS 3 atcML01XE18 201203012021031820210331ruxolitinib SKS 3 atcML01XE19 201304012021031820210331ridaforolimus SKS 3 atcML01XE21 201304012021031820210331regorafenib SKS 3 atcML01XE22 201304012021031820210331masitinib SKS 3 atcML01XE23 201404012021031820210331dabrafenib SKS 3 atcML01XE24 201404012021031820210331ponatinib SKS 3 atcML01XE25 201404012021031820210331trametinib SKS 3 atcML01XE26 201504012021031820210331cabozantinib SKS 3 atcML01XE27 201504012021031820210331ibrutinib SKS 3 atcML01XE28 201504012021031820210331ceritinib SKS 3 atcML01XE29 201604012021031820210331lenvatinib SKS 3 atcML01XE31 201604012021031820210331nintedanib SKS 3 atcML01XE32 201604012021031820210331cediranib SKS 3 atcML01XE33 201604012021031820210331palbociclib SKS 3 atcML01XE34 201604012021031820210331tivozanib SKS 3 atcML01XE35 201704012021031820210331osimertinib SKS 3 atcML01XE36 201704012021031820210331alectinib SKS 3 atcML01XE37 201704012021031820210331rociletinib SKS 3 atcML01XE38 201704012021031820210331cobimetinib SKS 3 atcML01XE39 201704012021031820210331midostaurin SKS 3 atcML01XE40 201704012021031820210331olmutinib SKS 3 atcML01XE41 201804012021031820210331binimetinib SKS 3 atcML01XE42 201804012021031820210331ribociclib SKS 3 atcML01XE43 201804012021031820210331brigatinib SKS 3 atcML01XE44 201904012021031820210331lorlatinib SKS 3 atcML01XE45 201904012021031820210331neratinib SKS 3 atcML01XE46 201904012021031820210331encorafenib SKS 3 atcML01XE47 201904012021031820210331dacomitinib SKS 3 atcML01XE48 201904012021031820210331icotinib SKS 3 atcML01XE50 201904012021031820210331abemaciclib SKS 3 atcML01XE51 202001012021031820210331acalabrutinib SKS 3 atcML01XE52 202001012021031820210331quizartinib SKS 3 atcML01XE53 202001012021031820210331larotrectinib SKS 3 atcML01XE54 202001012021031820210331gilteritinib SKS 3 atcML01XE56 202001012021031820210331entrectinib SKS 3 atcML01XE57 202001012021031820210331fedratinib SKS 3 atcML01XF 202104012021031825000101retinoider til cancerbehandling SKS 1 atcML01XF01 202104012021031825000101tretinoin SKS 1 atcML01XF02 202104012021031825000101alitretinoin SKS 1 atcML01XF03 202104012021031825000101bexaroten SKS 1 atcML01XG 202104012021031825000101proteasomhæmmere SKS 1 atcML01XG01 202104012021031825000101bortezomib SKS 1 atcML01XG02 202104012021031825000101carfilzomib SKS 1 atcML01XG03 202104012021031825000101ixazomib SKS 1 atcML01XH 202104012021031825000101histondeacetylase (HDAC) hæmmere SKS 1 atcML01XH01 202104012021031825000101vorinostat SKS 1 atcML01XH02 202104012021031825000101romidepsin SKS 1 atcML01XH03 202104012021031825000101panobinostat SKS 1 atcML01XH04 202104012021031825000101belinostat SKS 1 atcML01XH05 202104012021031825000101entinostat SKS 1 atcML01XJ 202104012021031825000101hedgehog pathway hæmmere SKS 1 atcML01XJ01 202104012021031825000101vismodegib SKS 1 atcML01XJ02 202104012021031825000101sonidegib SKS 1 atcML01XJ03 202104012021031825000101glasdegib SKS 1 atcML01XK 202101262021031825000101poly (ADP-ribose) polymerase (PARP) hæmmere SKS 1 atcML01XK01 202104012021031825000101olaparib SKS 1 atcML01XK02 202104012021031825000101niraparib SKS 1 atcML01XK03 202104012021031825000101rucaparib SKS 1 atcML01XK04 202104012021031825000101talazoparib SKS 1 atcML01XK05 202101262021031825000101veliparib SKS 1 atcML01XX14 199705162021031820210331tretinoin SKS 3 atcML01XX17 199705162021031820210331topotecan SKS 3 atcML01XX19 199705162021031820210331irinotecan SKS 3 atcML01XX22 200001012021031820210331alitretinoin SKS 3 atcML01XX25 200105012021031820210331bexaroten SKS 3 atcML01XX32 200404012021031820210331bortezomib SKS 3 atcML01XX38 200904012021031820210331vorinostat SKS 3 atcML01XX39 200904012021031820210331romidepsin SKS 3 atcML01XX42 201203012021031820210331panobinostat SKS 3 atcML01XX43 201304012021031820210331vismodegib SKS 3 atcML01XX45 201404012021031820210331carfilzomib SKS 3 atcML01XX46 201504012021031820210331olaparib SKS 3 atcML01XX47 201504012021031820210331idelalisib SKS 3 atcML01XX48 201604012021031820210331sonidegib SKS 3 atcML01XX49 201604012021031820210331belinostat SKS 3 atcML01XX50 201604012021031820210331ixazomib SKS 3 atcML01XX54 201804012021031820210331niraparib SKS 3 atcML01XX55 201804012021031820210331rucaparib SKS 3 atcML01XX56 201804012021031820210331etirinotecan pegol SKS 3 atcML01XX60 201904012021031820210331talazoparib SKS 3 atcML01XX61 201904012021031820210331copanlisib SKS 3 atcML01XX63 202001012021031820210331glasdegib SKS 3 atcML01XX64 202001012021031820210331entinostat SKS 3 atcML01XX65 202001012021031820210331alpelisib SKS 3 atcML01XX68 202001012021031820210331belotecan SKS 3 atcML01XX69 202101262021031825000101lurbinectedin SKS 1 atcML01XY02 202101262021031825000101pertuzumab og trastuzumab SKS 1 atcML04AA47 202101262021031825000101inebilizumab SKS 1 atcMM09AX11 202101262021031825000101palovaroten SKS 1 atcMN02AA11 202101262021031825000101oxymorphon SKS 1 atcMN03AX25 202101262021031825000101cenobamat SKS 1 atcMN03AX26 202101262021031825000101fenfluramin SKS 1 atcMP01BF04 201104012021031820210331artesunat, sulfamethopyrazin og pyrimethamin SKS 3 atcMP01BF04 202104012021031825000101artesunat, sulfalen og pyrimethamin SKS 1 atcMR01AD59 202101262021031825000101mometason, kombinationer SKS 1